Opendata, web and dolomites

NeoCellBank

A revolutionary regenerative therapy for management of chronic inflammatory diseases based on neonatal Mesenchymal Stem Cells

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 NeoCellBank project word cloud

Explore the words cloud of the NeoCellBank project. It provides you a very rough idea of what is the project "NeoCellBank" about.

neonatal    lifestyle    oa    expensive    finalise    rely    shared    industrialization    earn    pay    26    mostly    people    sedentary    underlying    animals    pets    therapy    experiencing    inflammation    19    solutions    amplification    humans    accessible    tissue    adult    veterinary    human    multiple    introducing    biological    joint    medicine    nsaids    solution    context    reverse    lengthy    incurring    mainly    abundant    appears    market    stronger    return    pathology    status    economic    diseases    stem    profits    pro    mechanism    limits    regeneration    accelerator    reaching    incidence    individual    symptoms    limited    recipients    effort    15    hire    good    off    involve    lower    donor    source    vetbiobank    investment    regenerative    commercial    hold    material    overcome    completion    revolutionize    euros    chronic    estimating    alternative    pharmacological    therapies    disrupt    mature    ageing    autologous    altered    inflammatory    endogenous    age    anti    profile    invasive    treatments    million    allogeneic    cell    immunogenicity    20    advantages    osteoarthritis    stage    society    palliative    foresee    burden    unrestricted    cells    disability   

Project "NeoCellBank" data sheet

The following table provides information about the project.

Coordinator
VETBIOBANK SAS 

Organization address
address: 1 AVENUE BOURGELAT
city: MARCY-L'ETOILE
postcode: 69280
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Project website https://www.vetbiobank.com/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-05-01   to  2019-08-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    VETBIOBANK SAS FR (MARCY-L'ETOILE) coordinator 50˙000.00

Map

 Project objective

Society is experiencing a rise in chronic inflammatory diseases, mostly due to ageing, and sedentary lifestyle. Osteoarthritis (OA) is one of the leading inflammatory diseases, affecting both humans (incidence 15%) and pets (20%), incurring disability and large economic burden. Current pharmacological treatments for OA involve palliative therapies (NSAIDs) that work on the symptoms, becoming lengthy and expensive with multiple side effects. In this context, regenerative medicine based on stem cells appears as a good alternative, as they reverse the pro-inflammatory status of the joint and promote endogenous tissue regeneration. However, current solutions for OA mainly rely on autologous adult stem cells, obtained through invasive procedures and which hold biological properties altered by donor age and underlying inflammation. Allogeneic adult cells could be used in any individual, but a limited amplification potential limits the number of recipients. In response, we aim to revolutionize the field of regenerative medicine by introducing a unique cell therapy based on neonatal stem cells. These cells have many advantages over adult cells: source material is accessible & abundant, cells show stronger anti-inflammatory properties, and lower immunogenicity profile which allows for unrestricted allogeneic use. The main goal of our project is to finalise industrialization and bring to market our reliable cell-based solution for OA. In Phase 1 we will define the technical and commercial steps to overcome before reaching mature stage. Upon completion of this project, we foresee our product to disrupt the veterinary market of inflammatory diseases. Moreover, since the pathology mechanism for OA is shared between animals and humans, our product could work as an accelerator for human applications. Importantly, the effort will pay off for Vetbiobank, estimating to earn €26 million profits, hire 19 people and reach a Return of Investment of 4.2 Euros after 5 years in the market.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "NEOCELLBANK" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "NEOCELLBANK" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

DNA DS (2019)

DNA Data storage

Read More  

ERGOVIAkinematix (2018)

New wearable measurement devices for Industry 4.0 based on gaming motion-capture system

Read More  

Magnesys (2019)

Efficient filtering of metallic impurities in food processing

Read More